



BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

December 2, 2020

Mainz, Germany, December 02, 2020 (GLOBE NEWSWIRE) – [BioNTech SE](#) (Nasdaq: BNTX, "BioNTech" or "the Company") will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2. The event will be held in English:

International press conference at 12.30pm CET / 6.30am ET

Please register [here](#).

Interested journalists may dial in 10-15 minutes before the conference starts. They will be able to submit questions via an online tool.

Participants may also access the press conference, including the video webcast, on <https://biontech.de/> under "Events & Presentations" in the Investor & Media section of the website. A recording of the press conference will be available on the same day. Additional media materials including images and videos can be accessed through the following link: [press kit](#).

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.de.

BioNTech Contacts

Media Relations

Jasmina Alatovic
Director External Communications
+49 6131 9084-0
Media@biontech.de

Investor Relations

Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
+49 (0)6131 9084 1074
Investors@biontech.de